- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01936337
Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients
August 11, 2014 updated by: Delenex Therapeutics AG
A Multi-center, Double-blinded, Randomized, Placebo-controlled, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of a Topical Application of DLX105 Onto Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris
In this study, the safety, tolerability and efficacy of DLX105 administered topically onto the psoriatic lesion of mild-to-moderate psoriasis patients will be investigated.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
59
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed and dated informed consent prior to initiation of any study procedures.
- Male or female Caucasian aged 18-75 years.
- Male or female patients with stable chronic mild-to-moderate plaque-type psoriasis (PASI ≤15).
- Male or female Caucasian patients with stable chronic mild-to-moderate plaque-type psoriasis (PASI ≤15) aged 18-75 years who must have at least two psoriasis lesions of >9 cm2 (located at arms and/or trunk, excluding elbows and legs), stable for at least 3 months, local PASI score ≥8.
- Affected body surface area (BSA) ≤10%.
- Negative pregnancy test for females of child-bearing potential (pre-menopausal, <2 years post-menopausal, not surgically sterile).
- Willing and able to participate in the trial as an outpatient and comply with all trial requirements.
Exclusion Criteria:
- Forms of psoriasis other than chronic plaque-type only (e.g., pustular, erythrodermic and guttate psoriasis, palmar, plantar or nail disease) at screening.
- Drug-induced psoriasis (i.e., new onset or current exacerbation from beta-blockers, calcium channel inhibitors or lithium) prior to randomization
Ongoing use of prohibited psoriasis treatments (duration of washout, i.e. discontinuation prior to randomization):
- Biological agents, e.g. adalimumab, etanercept, infliximab, ustekinumab, alefacept (12 weeks)
- Systemic therapy for psoriasis and psoriatic arthritis (other than above) e.g. methotrexate, cyclosporin, fumaric acid (derivatives), systemic steroids (4 weeks)
- Photochemotherapy e.g., ultraviolet A with psoralen (PUVA) (4 weeks)
- Phototherapy e.g., ultraviolet A (UVA) or ultraviolet B (UVB) (2 weeks)
- Topical therapies for the treatment of Ps such as corticosteroids, vitamin D analogues or retinoids within 14 days prior to baseline
- Other investigational psoriasis drugs (4 weeks or 5 half-lives, whichever is longer)
- Intake of any investigational drug or participation in a Clinical Trial within 4 weeks or 5 half-lives, (whichever is longer) prior to baseline.
- History or evidence of active tuberculosis. All patients will be tested for tuberculosis status using a blood test (QuantiFERON TB-Gold) unless this test has been performed within 4 months prior to randomization and was negative. Patients with evidence of latent tuberculosis may enter the trial after sufficient treatment has been initiated according to local regulations.
- Active systemic infections (other than common cold) during the two weeks before randomization
- Positive test for hepatitis B or C at screening
- Positive test for HIV at screening
- History or symptoms of malignancy of any organ system (other than history of basal cell carcinoma and / or up to three squamous cell carcinomas of the skin, if successful treatment has been performed, with no signs of recurrence; actinic keratosis, if present at screening, should be treated according to standard therapy before randomization), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- History of severe hypersensitivity to any human or humanized biological agents
- Any severe, progressive or uncontrolled medical condition at baseline that in the judgment of the investigator prevents the patient from participating in the study.
- Any clinically significant abnormal laboratory tests at screening
- Active liver disease with alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) > 3 x upper limit of normal at screening
- History of moderate or severe congestive heart failure (New York Heart Association [NYHA] class III or IV)
- Inability or unwillingness to undergo repeated venipunctures (e.g., due to poor tolerability or lack of access to veins)
- History or evidence of drug or alcohol abuse within the 6 months prior first study drug administration
- Patients who had live vaccination within 6 weeks prior first study drug administration, or will require live vaccination during the course of the trial
- History of hypersensitivity to any of the excipients of the study drugs or to excipients of similar chemical classes
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (HCG) laboratory test (> 5 mIU/mL)
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. UNLESS they are women whose partners have been sterilized by vasectomy
- Using a highly effective method of birth control (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, condoms (by the partner), and intrauterine devices (IUDs)). Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not considered acceptable forms of birth control within this study
- Reliable contraception should be maintained throughout the study and for 2 weeks after the last study drug administration
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Hydrogel
|
topical administration on psoriatic plaque
|
Active Comparator: DLX105 Hydrogel
|
topical administration on psoriatic plaque
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of local tolerability by the investigator
Time Frame: up to 6 weeks
|
using a validated score for each treatment area
|
up to 6 weeks
|
assessment of local tolerability sensations by the patient
Time Frame: up to 6 weeks
|
using a visual analogue scale for each treatment area
|
up to 6 weeks
|
collection of Adverse Events
Time Frame: up to 6 weeks
|
up to 6 weeks
|
|
Determination of efficacy of DLX105 as compared to baseline
Time Frame: Baseline to Week 4
|
assessment of Local PASI score per plaque measured at week 4 compared to baseline
|
Baseline to Week 4
|
Determination of efficacy of DLX105 as compared to Placebo at week 4
Time Frame: baseline to week 4
|
Local PASI difference at week 4 between DLX105 and placebo
|
baseline to week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detection of Immunogenicity
Time Frame: up to 6 weeks
|
Anti-drug-antibodies will be determined to assess the immunogenic potential of DLX105.
|
up to 6 weeks
|
Detection of Pharmacokinetics
Time Frame: up to 6 weeks
|
Pharmacokinetics through levels will be measured in serum at 4 time points over 6 weeks.
|
up to 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (Actual)
June 1, 2014
Study Completion (Actual)
July 1, 2014
Study Registration Dates
First Submitted
August 28, 2013
First Submitted That Met QC Criteria
September 3, 2013
First Posted (Estimate)
September 6, 2013
Study Record Updates
Last Update Posted (Estimate)
August 12, 2014
Last Update Submitted That Met QC Criteria
August 11, 2014
Last Verified
August 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DLX105-003-002-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis Vulgaris
-
LEO PharmaCompletedPlaque Psoriasis | Psoriasis VulgarisGermany
-
SoligenixRecruitingPsoriasis | Plaque Psoriasis | Psoriasis VulgarisUnited States
-
LEO PharmaTerminatedPsoriasis | Plaque Psoriasis | Psoriasis VulgarisBelgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
-
PRCL Research Inc.CompletedPlaque Psoriasis | Psoriasis VulgarisCanada, Slovakia, Ukraine
-
Chinese University of Hong KongNot yet recruitingPsoriasis Vulgaris
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University of California, San FranciscoNovartis Pharmaceuticals; National Psoriasis FoundationRecruitingPsoriasis VulgarisUnited States
-
University of California, San FranciscoSun Pharmaceutical Industries LimitedRecruiting
-
Centre for Human Drug Research, NetherlandsJanssen PharmaceuticalsRecruiting
Clinical Trials on DLX105 Hydrogel
-
DelArrivo, Inc.Completed
-
Delenex Therapeutics AGCompletedMild-to-moderate Psoriasis VulgarisAustria, Germany
-
Delenex Therapeutics AGCompletedFistulizing Crohn's DiseaseSwitzerland
-
University of WashingtonNational Cancer Institute (NCI)CompletedBladder CarcinomaUnited States
-
Halscion, Inc.Completed
-
University of VirginiaMicrovention-Terumo, Inc.Terminated
-
Chulalongkorn UniversityNot yet recruitingWound | Skin Graft Scar | Donor Site Complication | Scar Conditions and Fibrosis of SkinThailand
-
PromedonActive, not recruitingPain | Osteoarthritis, KneeArgentina
-
Melva LouisaTerminated
-
Peking Union Medical College HospitalShanghai Reunion Biotech Co.,Ltd.RecruitingUterine Cervical NeoplasmsChina